1. Phase I trial of topotecan (TT) administered by 24-hour infusion without and with G-CSF;Abbruzzese;Proceedings of the American Association for Cancer Research,1993
2. High-dose intensity of CPT-11 administered as single dose every 3 weeks: The Institut Gustave Roussy experience;Abigerges;Proceedings of the American Society for Clinical Oncology,1993
3. Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II;Anzai;Proceedings of the American Association for Cancer Research,1992
4. Preclinical evaluation of CPT-11, a camptothecin derivative;Bissery;Proceedings of the American Association for Cancer Research,1991
5. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion;Blaney;Cancer Res,1993